Deepro R. Mukerjee

Based on a review of his professional background and tracked court appearances, this is a summary of Deepro R. Mukerjee's patent litigation practice.

Deepro R. Mukerjee is the chair of the global Intellectual Property department at Katten Muchin Rosenman LLP, where he is also a member of the firm's Executive Committee and Board of Directors. His practice is heavily focused on patent litigation for the life sciences industry, where he serves as lead trial counsel for some of the world's largest generic pharmaceutical companies in complex Hatch-Waxman (ANDA) litigation. While best known for his pharmaceutical work, Mr. Mukerjee's litigation experience also covers a diverse range of technologies, including biotechnology, medical devices, voice recognition software, business methods, and plant patents.

The authoritative case data tracks a single appearance on the plaintiff side for Visa USA Inc. However, Mr. Mukerjee's practice, as widely reported, is centered on representing generic pharmaceutical companies, which typically act as defendants or declaratory judgment plaintiffs when challenging patents on branded drugs. He has secured numerous favorable outcomes, including a notable victory in a rare plant patent case for a produce distributor where the claims were dismissed and the patent-in-suit was assigned to his client. Other successes include invalidating multiple patent claims at the claim construction stage in the Southern District of New York and obtaining a Federal Circuit affirmance of invalidity for patents concerning a Type II diabetes treatment.

Mr. Mukerjee joined Katten in 2018 from Alston & Bird LLP. His practice includes proceedings before the Patent Trial and Appeal Board (PTAB), where he has experience managing inter partes reviews (IPRs). He is admitted to practice in New York.